



UNIVERSITI PUTRA MALAYSIA

***DEVELOPMENT OF BACTERIOPHAGE ϕ KAZ14 LOADED CHITOSAN
NANOPARTICLES FOR BIOLOGICAL CONTROL OF COLIBACILLOSIS
IN CHICKENS***

ADAMU AHMAD KAIKABO

FSTM 2016 2



**DEVELOPMENT OF BACTERIOPHAGE Φ KAZ14 LOADED
CHITOSAN NANOPARTICLES FOR BIOLOGICAL CONTROL OF
COLIBACILLOSIS IN CHICKENS**

By

ADAMU AHMAD KAIKABO

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in
Fulfillment of the Requirements for the Degree of Doctor of Philosophy**

June 2016

COPYRIGHT

All material contained within the thesis, including without limitation text, logos, icons, photographs and all other artwork, is a copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be of any material contained within the thesis for non-commercial purposes from the copyrighted holder. Commercial use of material may only be made with express, prior, written permission of Universiti Putra Malaysia.

Copyright© Universiti Putra Malaysia



DEDICATION

To the

Memories of

My late mother Hauwa, elder and younger sisters Aisha and Salamatu Muhammad Kaikabo Adamu. May Allah bless their souls and admit them into al-jannatul Firdaus.

...and

My children

Adama (Hamra), Hajara (Khairat), Sumayya and AbdurRahman (Arafat)



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfillment of the requirement for the Degree of Doctor of Philosophy

DEVELOPMENT OF BACTERIOPHAGE Φ KAZ14 LOADED CHITOSAN NANOPARTICLES FOR BIOLOGICAL CONTROL OF COLIBACILLOSIS IN CHICKENS

By

ADAMU AHMAD KAIKABO

June 2016

Chairman : Abdulkarim Sabo Mohammed, PhD
Faculty : Food Science and Technology

Bacteriophage Φ KAZ14 was applied in the biological control of colibacillosis. It had lytic activity on APEC 01: K1:H7 and β lactamase producing *Escherichia coli*. The icosahedral head of the phage measured 50 nm by 45 nm and long contractile tail of 78 nm by 10 nm. Its multiplicity of infection (MOI) was 0.01, the latent period of infection of 15 minutes and burst size of 80 particles per infected cell. The phage survived a pH range of 5.0 to 14, and resistant to a temperature of 65 °C. C-NPs protected the phage from enzymatic degradation *in vitro*. The spherical C-NPs had average particle size range from 176 \pm 3.2 to 188 \pm 7.4 nm, a zeta potential of 60.3 \pm 0.2 and 50.5 \pm 0.4 and polydispersity index (PDI) of 0.506 and 0.472. Fourier transform infrared spectroscopy (FTIR) showed no difference between C- Φ KAZ14 NP and C-NP. Thermal analysis showed the temperature of -20 °C is desirable for storage. C- Φ KAZ14 NPs were not toxic on chorioallantoic membrane. Treatment with C- Φ KAZ14 NPs decrease viable bacterial counts in feces and colonization in the intestine of chickens ($p \leq 0.05$). It also significantly decreased mortality rate in *E. coli*-challenged birds ($p \leq 0.05$). C- Φ KAZ14 NPs increased bodyweight of chickens ($p \leq 0.05$). Lesions were not observed in major organs. C- Φ KAZ14 NPs therapy is a beneficial control strategy against colibacillosis in chickens.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk Ijazah Doktor Falsafah

PEMBANGUNAN BAKTERIOFAJ Φ KAZ14 SARAT NANOPARTIKEL CHITOSAN BAGI KAWALAN BIOLOGI COLIBACILLOSIS PADA AYAM

Oleh

ADAMU AHMAD KAIKABO

Jun 2016

Pengerusi : Abdulkarim Sabo Mohammed, PhD.
Fakulti : Sains dan Teknologi Makanan

Bakteriofaj Φ KAZ14 telah digunakan dalam kawalan biologi colibacillosis. Ia mempunyai aktiviti pemusnahan pada APEC 01: K1: H7 dan *Escherichia coli* yang menghasilkan β lactamase. Kepala icosahedral daripada faj yang diukur 50 nm sebanyak 45 nm dan ekor panjang contractile 78 nm oleh 10 nm. Kepelbagaian jangkitan (MOI) adalah 0.01, tempoh pendam jangkitan 15 minit dan saiz pecah adalah 80 zarah bagi setiap sel dijangkiti. Faj terselamat pada julat pH 5.0 hingga 14, dan tahan suhu hingga 65 °C. C-NPS melindungi faj dari kemusnahan enzim in vitro. C-NPs sfera mempunyai purata julat saiz zarah dari 176 \pm 3.2 ke 188 \pm 7.4 nm, potensi zeta 60.3 \pm 0.2 dan 50.5 \pm 0.4 dan indeks polikeselerakan (PDI) pada 0.506 dan 0.472. Spektroskopi inframerah ubah Fourier (FTIR) menunjukkan tiada perbezaan antara C- Φ KAZ14 NP dan C-NP. Analisis terma menunjukkan suhu -20 °C adalah wajar untuk penyimpanan. C- Φ KAZ14 NPs adalah tidak toksik terhadap membran chorioallantoic. Rawatan dengan C- Φ KAZ14 NPS mengurangkan bilangan bakteria berdaya maju dalam najis dan pengkolonian dalam usus ayam ($p \leq 0.05$). Ia juga menurunkan kadar kematian dengan ketara dalam burung yang dijangkiti E. coli ($p \leq 0.05$). C- Φ KAZ14 NPs meningkatkan berat badan ayam ($p \leq 0.05$). Luka-luka tidak didapati dalam organ-organ utama. Terapi C- Φ KAZ14 NPs adalah strategi kawalan bermanfaat menentang colibacillosis pada ayam.

ACKNOWLEDGEMENTS

In the name of Allah, the most Gracious, the most Merciful. All beautiful praises are due to Allah alone, the creator and the sustainer of every living being on the earth. It is by His special grace mankind has learned how to read and write. I wish to express my profound gratitude to my supervisor, Associate Professor Dr. Abdulkarim Sabo Mohammed for his continuing patience, untiring support, and guidance during the course of this study. He has provided a levelled ground for me to achieve this objective of earning a degree of Doctor of Philosophy (Ph.D.). In a similar manner, I wish to thank Associate Professor Dr. Faridah Abas. I appreciate the role she played in the purchase of one hundred COBB 500 broiler chicks with their feeds which I used during the animal studies. I thanked friends Drs. Abdul Rasheed Bello Aliyu, Gimba Fufa Ido, Dahiru Sani, Kabiru Kalgo, Mr. Ahmad Mediani and Miss Fatihanim Haji Mohammed Nor for various help rendered. I am indebted to my parents for their concern, prayers and good wishes and my family; Amina my wife and children; Adama, Hajara, Sumayya and Abdurrahman for their enduring patience while I was away for study. For those who helped and deserves to be acknowledged but due to space constraints please bear with me I pray may Allah rewards you all.

I certify that a Thesis Examination Committee has met on 14 June 2016 to conduct the final examination of Adamu Ahmad Kaikabo on his thesis entitled "Development of Bacteriophage Φ KAZ14-Loaded Chitosan Nanoparticles for Biological Control of Colibacillosis in Chickens" in accordance with the Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded the Doctor of Philosophy.

Members of the Thesis Examination Committee were as follows:

Seyed Hamed Mirhosseini, PhD

Associate Professor
Faculty of Food Science and Technology
Universiti Putra Malaysia
(Chairman)

Son Radu, PhD

Professor
Faculty of Food Science and Technology
Universiti Putra Malaysia
(Internal Examiner)

Rasedee @ Mat bin Abdullah, PhD

Professor
Faculty of Veterinary Medicine
Universiti Putra Malaysia
(Internal Examiner)

Debabrata Biswas, PhD

Assistant Professor
University of Maryland
United States
(External Examiner)



ZULKARNAIN ZAINAL, PhD

Professor and Deputy Dean
School of Graduate Studies
Universiti Putra Malaysia

Date: 23 August 2016

This thesis was submitted to the Senate of the Universiti Putra Malaysia and has been accepted as fulfillment of the requirement for the degree of Doctor of Philosophy. The members of the Supervisory Committee were as follows:

Abdulkarim Sabo Mohammed, PhD

Associate Professor
Faculty of Food Science and Technology
Universiti Putra Malaysia
(Chairman)

Faridah Abas, PhD

Associate Professor
Faculty of Food Science and Technology
Universiti Putra Malaysia
(Member)

Sieo Chin Chin, PhD

Associate Professor
Faculty of Biotechnology and Biomolecular Sciences
Universiti Putra Malaysia
(Member)

BUJANG BIN KIM HUAT, PhD

Professor and Dean
School of Graduate Studies
Universiti Putra Malaysia

Date

Declaration by graduate student

I hereby confirm that:

- this thesis is my original work;
- quotations, illustrations and citations have been duly referenced;
- this thesis has not been submitted previously or concurrently for any other degree at any institutions;
- intellectual property from the thesis and copyright of thesis are fully-owned by Universiti Putra Malaysia, as according to the Universiti Putra Malaysia (Research) Rules 2012;
- written permission must be obtained from supervisor and the office of Deputy Vice-Chancellor (Research and innovation) before thesis is published (in the form of written, printed or in electronic form) including books, journals, modules, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other materials as stated in the Universiti Putra Malaysia (Research) Rules 2012;
- there is no plagiarism or data falsification/fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) and the Universiti Putra Malaysia (Research) Rules 2012. The thesis has undergone plagiarism detection software

Signature: _____ Date: _____

Name and Matric No.: Adamu Ahmad Kaikabo, GS32292

Declaration by Members of Supervisory Committee

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) were adhered to.

Signature: _____
Name of Chairman
of Supervisory
Committee: Associate Professor Dr. Abdulkarim Sabo Mohammed

Signature: _____
Name of Member
of Supervisory
Committee: Associate Professor Dr. Faridah Abas

Signature: _____
Name of Member
of Supervisory
Committee: Associate Professor Dr. Sieo Chin Chin

TABLE OF CONTENTS

		Page
ABSTRACT		i
ABSTRAK		ii
ACKNOWLEDGEMENTS		iii
APPROVAL		iv
DECLARATION		vi
LIST OF TABLES		xii
LIST OF FIGURES		xiii
LIST OF PLATES		xiv
LIST OF ABBREVIATIONS		xv
CHAPTER		
1	INTRODUCTION	1
	1.1 Background of the study	1
	1.2 Problem statement	2
	1.3 Significance of the study	2
	1.4 Objectives of the study	3
2	LITERATURE REVIEW	4
	2.1 The Malaysia's poultry industry	4
	2.2 Global issues and challenges in poultry industry	5
	2.2.1 Social changes and consumer knowledge on food safety	5
	2.2.2 Emergence of antibiotic-resistant strains	6
	2.2.3 Re-emerging diseases of poultry	7
	2.3 Avian pathogenic <i>Escherichia coli</i> infection	7
	2.3.1 The Biology of <i>Escherichia coli</i>	7
	2.3.2 The burden of <i>Escherichia coli</i> in poultry industry	8
	2.4 The consequences of <i>Escherichia coli</i> infection to poultry meat production	9
	2.5 Antibiotics resistance and issues in poultry production	9
	2.6 Implications of avian pathogenic <i>Escherichia coli</i> in food chain	9
	2.7 APEC as a potential hazard to food safety	11
	2.8 Poultry: A reservoir for extraintestinal pathogenic <i>Escherichia coli</i>	12
	2.9 The biology and life cycle of Bacteriophages	13
	2.9.1 The classification of Bacteriophages	15
	2.10 Bacteriophage: Applications in food safety and the control of foodborne pathogens	16
	2.10.1 Phage therapy	16
	2.10.2 Applications of Bacteriophage therapy in food safety	17
	2.11 Bacteriophage in the biological control of foodborne pathogens	17
	2.12 Problems associated with bacteriophage therapy	18
	2.12.1 Phage clearance by reticuloendothelial system	18
	2.12.2 The evolution of phage-neutralizing antibodies	18
	2.12.3 The development of phage resistance	18
	2.12.4 Endotoxin release from destroyed host cell	19

2.13	A brief overview of chitosan as a biological polymer for the synthesis of Nanoparticles	19
2.13.1	Chitosan	19
2.13.2	Interactions of chitosan with biological materials	19
2.13.3	Chitosan nanoparticles as delivery carriers for Bacteriophage	20
3	ISOLATION AND CHARACTERIZATION OF BACTERIOPHAGE LYTIC TO <i>Escherichia coli</i> FROM CHICKENS	21
3.1	Introduction	21
3.2	Materials and methods	22
3.3	Chemical reagents and media	22
3.3.1	Host bacterial strain used in the isolation of bacteriophage	22
3.4	Medium	22
3.4.1	Culture and revival of host Bacterial strain	23
3.5	Isolation of Bacteriophage lytic to <i>Escherichia coli</i>	23
3.6	Host range and lytic spectrum of isolated Bacteriophage	24
3.7	Identification of the isolated Bacteriophage	24
3.7.1	Transmission electron microscopy	24
3.7.2	Molecular identification of isolated Bacteriophage	24
3.8	Results	25
3.8.1	Host range and lytic spectrum of isolated Bacteriophage Φ KAZ14	25
3.8.2	Identification of isolated Φ KAZ14 Bacteriophage	26
3.8.3	The growth pattern of Φ KAZ14 Bacteriophage	28
3.8.4	The effects of temperature on viability of Bacteriophage Φ KAZ14	28
3.8.5	The effects of pH on the stability of Bacteriophage Φ KAZ14	29
3.9	Discussion	30
4	PREPARATION AND CHARACTERIZATION OF BACTERIOPHAGE ΦKAZ14 LOADED CHITOSAN NANOPARTICLES	33
4.1	Introduction	33
4.2	Materials and methods	33
4.3	Preparation of Bacteriophage-based Chitosan Nanoparticles	33
4.4	Bacteriophage Propagation and Titration	33
4.5	Formulation of Bacteriophage Φ KAZ14 Chitosan Nanoparticles	34
4.6	Characterization of Chitosan- Φ KAZ14 Bacteriophage Nanoparticles	34
4.6.1	Scanning Electron Microscopy	34
4.6.2	Evaluation of the properties of Chitosan- Φ KAZ14 Bacteriophage Nanoparticles	34
4.6.3	Fourier Transform Infrared spectroscopy of Φ KAZ14 Bacteriophage Chitosan Nanoparticles	35
4.6.4	Thermal stability of Φ KAZ14 Bacteriophage Chitosan Nanoparticles	35

4.6.5	Protection Bacteriophage Φ KAZ14 Chitosan from degradation by enzyme and simulated gastric pH	35
4.6.6	In vitro release of bacteriophage Φ KAZ14 from C- Φ KAZ14	36
4.6.7	Evaluation of cytotoxicity using chorioallantoic membrane assay	36
4.7	Results	36
4.7.1	Morphology of chitosan Bacteriophage Φ KAZ14 loaded nanoparticles	36
4.7.2	Physicochemical characterization of C- Φ KAZ14 NP	37
4.7.3	FTIR of Chitosan Bacteriophage Φ KAZ14 loaded Nanoparticles	38
4.7.4	Effects of enzyme on chitosan Bacteriophage Φ KAZ14 loaded Nanoparticles	39
4.7.5	Differential scanning calorimetry of Chitosan Bacteriophage Φ KAZ14 loaded Nanoparticles	39
4.7.6	Effects of gastric pH on Bacteriophage Φ KAZ14 Nanoparticles	40
4.7.7	In vitro release of bacteriophage Φ KAZ14 from C- Φ KAZ14	41
4.7.8	Evaluation of the toxicity of Bacteriophage Φ KAZ14 Nanoparticles	41
4.8	Discussions	43
5	EVALUATION OF THE EFFICACY OF BACTERIOPHAGE ΦKAZ14 LOADED CHITOSAN NANOPARTICLES ON E. coli IN COBB 500 BROILER CHICKENS	48
5.1	Introduction	48
5.2	Materials and methods	48
5.2.1	Evaluation of the efficacy of C- Φ KAZ14 NPs in COBB 500 Broiler Chicks	48
5.2.2	Trial experiments	49
5.2.3	Evaluation of the clinical signs of the infected experimental chicks	50
5.2.4	Measurements of body weights changes in the experimental chicks	50
5.2.5	Assessment of mortality rates in the experimental chicks	50
5.2.6	Colonization and shedding of Avian pathogenic <i>Escherichia coli</i> in the feces of experimental Chicks	50
5.2.7	Observation on lesions on the major organs in experimental Chicks	51
5.3	Statistical analysis	51
5.4	Results	51
5.4.1	Clinical signs of COBB 500 Broiler Chicks infected with Avian pathogenic <i>Escherichia coli</i>	51
5.4.2	Weekly body weights of COBB 500 Broiler Chicks infected with APEC	52
5.4.3	Mortality rates in COBB 500 broiler chicks infected with APEC	52

5.4.4	Bacterial colonization and shedding in feces of the infected Chicks	54
5.4.5	Lesion on the major organs of the experimental chicks	54
5.5	Discussions	56
6	SUMMARY, GENERAL CONCLUSION AND RECOMMENDATIONS FOR FUTURE RESEARCH	62
	REFERENCES	64
	APPENDICES	79
	BIODATA OF STUDENT	87
	LIST OF PUBLICATIONS	88



LIST OF TABLES

Table		Page
3.1	List of host bacterial strain	22
3.2	Bacteriophage Φ KAZ15 host lytic spectrum	26
4.1	Physicochemical characteristics of C- Φ KAZ14 and Chitosan nanoparticles	38
4.2	Differential scanning calorimetry (DSC) of Chitosan Φ KAZ14 Bacteriophage Loaded Nanoparticles	40
5.1	Weekly bacterial shedding rate (CFU/g) (mean \pm SD triplicate) in feces of COBB 500 broiler chicks infected with pathogenic <i>Escherichia coli</i> and treated with C- Φ KAZ14 NPs	54

LIST OF FIGURES

Figure	Page
2.1 The typical reproductive cycle of Bacteriophage	13
2.2 Structure of Chitosan	19
3.1 Plaques showing the presence of Bacteriophage Φ KAZ14 on Agar.	25
3.2 Scanning electron microscopy of isolated Φ KAZ14 Bacteriophage lytic to Avian pathogenic <i>Escherichia coli</i> O1:K1:H7	27
3.3 Gel electrophoresis picture showing g23 capsid gene in Φ KAZ14 Bacteriophage detected at 600bp	27
3.4 Growth pattern of Φ KAZ14 Bacteriophage lytic to APEC O1:K1:H7	28
3.5 Effects of temperature on the stability of Bacteriophage Φ KAZ14	29
3.6 Effects of pH on the viability of Bacteriophage Φ KAZ14	29
4.1 Micrograph of chitosan nanoparticles	37
4.2 Fourier transform infrared (FT-IR) spectra of blank C-NP and C- Φ KAZ14 NP	38
4.3 Gel electrophoresis picture of C- Φ KAZ14 NP (A) and naked Φ KAZ14 Bacteriophage (B) treated with the enzyme pepsin	39
4.4 The viability of C- Φ KAZ14 NP and free Φ KAZ14 Bacteriophage under different pH levels.	40
4.5 In vitro release characteristics of Φ KAZ14 from C- Φ KAZ14 NP incubated in simulated intestinal pH	41
4.6 Macroscopic and microscopic images of normal chorioallantoic membrane (CAM) after inoculation with C- Φ KAZ14 NP	42
4.7 Macroscopic and microscopic images of chorioallantoic membrane (CAM) following inoculation with 99.8% glacial acetic acid and incubation for 24 h. Arrows on Mc (macroscopic surfaces) show A = hemorrhages, B = angiogenesis. On microscopic image A and B = angiogenesis, C = hemorrhages on the CAM surface. The embryo died after 24 hours of incubation.	42
5.1 Average weekly body weight changes (Kg) of COBB 500 Broiler chicks infected with pathogenic <i>Escherichia coli</i> and treated with C Φ KAZ14 NPs. Φ KAZ14 phage = naked Bacteriophage, C- Φ KAZ14 NP = Chitosan Φ KAZ14 bacteriophage nanoparticle	52

- 5.2 Mortality rate in COBB 500 broiler chicks infected with APEC and treated with C-ΦKAZ14 NPs. ΦKAZ14 phage = free phage, C ΦKAZ14 NPs = chitosan Bacteriophage loaded nanoparticles. 53
- 5.3 Morbidity rate in COBB 500 broiler Chicks infected with pathogenic *Escherichia coli* and treated with C-ΦKAZ14 NPs 53



LIST OF PLATES

Plate		Page
5.1	COBB broiler Chicks infected with APEC O1:K1:H7 and treated with C-ΦKAZ14 NPs	51
5.2	Hearts of COBB broiler Chicks infected with pathogenic Escherichia coli and treated with C-ΦKAZ14 NPs. (A = untreated control; B = Naked ΦKAZ14; C= C-ΦKAZ14 NPs) pictures. Arrows showed slightly swollen hearts in A and B.	55
5.3	Livers of COBB broiler Chicks infected with pathogenic Escherichia coli and treated with C-ΦKAZ14 NPs. A = untreated control; B = Naked ΦKAZ14; C = C-ΦKAZ14 NPs). Arrows showed mottling of liver parenchyma.	55
5.4	Lungs of COBB broiler Chicks infected with pathogenic Escherichia coli and treated with C-ΦKAZ14 NPs. A = untreated control; B = Naked ΦKAZ14; C = C-ΦKAZ14 NPs. Arrows showed mild consolidation of lung tissues.	56

LIST OF ABBREVIATIONS

APEC	Avian pathogenic <i>Escherichia coli</i>
bp	Base pair
cP	Centipoise
CE	Communautés européennes
CAM	Chorioallantoic membrane assay
CHROMagar	Chromogenic agar
CNF	Chicken normal flora
C-NPs	Chitosan nanoparticles
C- Φ KAZ14	Chitosan phi kappa alpha zeta 14
CFU/mL	Colony forming unit per milliliter
ColV	Colicin V
DAL	Double agar layer
DSC	Differential scanning calorimetry
ds	double stranded
EC	European commission
EHEC	Enterohaemorrhagic <i>Escherichia coli</i>
Et	Endotoxin
ETEC	Enterotoxinogenic <i>Escherichia coli</i>
EPEC	Enteropathogenic <i>Escherichia coli</i>
ESBL	Extended spectrum beta lactamase
EU	European Union
FRD1	<i>Pseudomonas aeruginosa</i> strain
FTIR	Fourier transform infrared resonance
GC	Gas chromatography
GC-MS	Gas Chromatography Mass Spectrometry
HACCP	Hazard Analysis Critical Control Point
hCG	Human chorionic gonadotropin
HCN	Hydrogen cyanide

HUS	Hemolytic uremic syndrome
¹ H NMR	Proton Nuclear Magnetic Resonance
IFPRI	International Food Policy Research Institute
IL-6	Interleukin 6
kDA	Kilo Dalton
LBA	Luria Bertani Agar
LBB	Luria Bertani Broth
LPS	Lipopolysaccharide
LyD	Lysis deficient
L-glutamic acid	L-form of Glutamic acid
MS	Mass spectrometry
MRSA	Methicillin resistant <i>Staphylococcus aureus</i>
MSSA	Methicillin sensitive <i>Staphylococcus aureus</i>
M13 phage	M13 Bacteriophage
NEM	Newborn <i>Escherichia coli</i> Meningitis
nm	Nanometer
NMR	Nuclear Magnetic Resonance
NPs	Nanoparticles
PCR	Polymerase chain reaction
PDI	Polydispersity index
PFU/mL	Plaque forming unit per milliliter
PlyG	Phage lysin-Gamma
pH	Measure of acid base concentration
RES	Reticulo Endothelial System
RNA	Ribonucleic acid
rpm	Revolution per minute
16S rRNA	16S ribosomal RNA
SEM	Scanning electron microscopy
T lymphocytes	Thymus derived lymphocytes
Th 1	Thymus helper cells 1

Th 2	Thymus helper cells 2
TEM	Transmission electron microscopy
TMP-STX	Trimethoprim-Sulfamethoxazole
TNF	Tissue necrosis factor alpha
TPP	Tripolyphosphate
UTI	Urinary Tract Infection
v/v	Volume per volume
µm	Micrometer
µL	Microliter
%	Percentage
ΦKAZ14	Phi Kaikabo Azbak 14

CHAPTER 1

INTRODUCTION

1.1 Background of the study

Poultry sector is an important component of the livestock industry in Peninsular Malaysia and the world in general. This sector has metamorphosed into a progressive, coordinated, and advanced industry with egg and meat production worth between RM1.78 to RM6.03 billion annually. The global poultry meat consumption had increased from 66 million tonnes in 2000 to a calculated 106 million tonnes in 2013, and of this increase, nearly 40 % of the consumption rates were in Asia. Malaysia is self-reliant in the production of poultry meat (128%) and eggs (115%) required for its growing population (Jamaluddin, 2013). The poultry Subsector is the most adjustable and rapidly growing of the livestock sector. Poultry represents a substantial portion of food animal and contributes significantly to economic growth and food security globally (FAO, 2013). The annual chicken meat consumption per person will increase by 26% (FAO, 2010). An estimated 40% of the total world animal protein is contributed by the poultry industries in the year 2015 (IFPRI, 2000).

Malaysia even though is self-reliant in poultry meat and egg production have pertinent issues with regard to production and sustainability. As the poultry industry is expanding, the need to improve the efficiency of production will largely depend on the control and prevention of diseases. Infectious diseases are one of the major causes of economic losses in poultry industries which are also a food safety issue. Rapid growth in this industry is only possible with innovative advances in poultry management, nutrition, genetics and better diagnosis and control of diseases (Bagust, 2013).

On the global perspective, poultry production has been projected to increase by an unprecedented 119.4 million metric tonnes from the year 2012 to 2030, an increase of 31.6%. Among the top poultry producing countries, India is expected to top the list at 102.1%, Russia 45.2%, Brazil 40.1%, China 33.4%, United State 24.5%, and the European Union 7.4%. However, the trend is expected to decline by 0.7% from 733,000 to 728,000 metric tonnes chicken meat production in Egypt and a drop of 6.1% from 578,000 to 543,000 metric tonnes in Taiwan (USDA ERS, 2015).

Diseases of bacterial and viral origin are responsible for the decline in the growth of the poultry industry. Bacterial disease such as colibacillosis causes huge economic losses to the poultry industry worldwide (Youssef & Mansour, 2008). It is a major infectious disease observed in birds of all ages, thus regarded as one of the commonest infectious diseases of poultry that causes morbidity and mortality in young chicks (Li et al., 2005).

Practical strategies for the control of Colibacillosis besides biosecurity management are; chemotherapy using antibiotics or vaccination as preventive measures against infection.

However, control by antibiotics is largely compromised by the emergence and development of resistant strains to one or more antibiotics drugs of choice (Vandekerchove et al., 2005). Also, in some cases, the reappearance of colibacillosis outbreak does occur following stoppage of the antibiotic chemotherapy (Zanella et al., 2000). The possibility of transfer of resistance genes from animal to human bacteria strains has been observed, and this is of great concern to public health.

Vaccination as a control strategy is not without practical issues. Literature has shown that APEC strains are highly diverse. This diversity has limited the applicability of vaccine even with the use of a genetically produced vaccine. Killed or attenuated vaccines provide sufficient protection against infection with homologous strains only, but protection against heterologous strains is with limited success (Dho-moulin et al., 1999). The compounding effects of lack of vaccine protection against infections on the production, economy and food safety and security are enormous.

Alternatively, control of Colibacillosis may be achieved through biological control strategy through the use of Bacteriophages. Phage is viruses that kill bacteria, they are specific to pathogens. A bacteriophage is not harmful to plants, human, animals or the environment, thus offer a useful alternative for the control of colibacillosis. Bacteriophages are capable of infecting and killing target bacteria and thus an alternative to combating antibiotic resistance. The usefulness of Bacteriophage in control of Colibacillosis could be enhanced by encapsulation in materials like chitosan, which is a biodegradable biocompatible, nontoxic polymer which, when used in the encapsulation of a phage would protect and improve its delivery to the target sites of infection. This technology considered in this study.

1.2 Problem statement

Avian Pathogenic *Escherichia coli* is of potential concern to public health due the evidence of its possible role in causing human disease. It has been shown that *Escherichia coli* O2:K1 and O78 serotype can be isolated from infected human urinary tract and septicemic chickens.

Avian Pathogenic *Escherichia coli* colonizes gastrointestinal tract of chicken and this sometimes contributes to carcass contamination at slaughter and environmental pollution due to the fecal shedding of the organisms.

1.3 Significance of the study

Public health concerns arising from food safety are a burning issue in global trade of animal products and poultry in particular. In order to mitigate food safety risks; animal-derived food products, especially of poultry origin must be safe for human consumption. The strategy of using encapsulated or loaded bacteriophage in nanoparticles as a biocontrol agent could lead to the reduction in intestinal colonization of APEC and shedding into the environment, and would significantly reduce carcass contamination at

the slaughter.

1.4 Objectives of the study

The main objective of the current study was to prepare coliphage loaded in chitosan nanoparticles for the biocontrol of colibacillosis in chickens, and the specific objectives are:

1. To isolate and characterized lytic bacteriophage for the biological control of APEC O1:K1:H7
2. To prepare and characterized chitosan nanoparticle for the encapsulation of bacteriophage lytic to APEC O1:K1:H7
3. To evaluate in vivo efficacy of bacteriophage(s) encapsulated in chitosan nanoparticles for the biological control of APEC O1:K1:H7 in Chickens.

REFERENCES

- Acar, J. F., & Moulin, G. (2006). Antimicrobial resistance at farm level. *Revue scientifique et technique (International Office of Epizootics)*, 25(2), 775-792.
- Ackermann, H. W., Nguyen, T. M. (1983). Sewage coliphages studied by electron microscopy. *Applied and Environmental Microbiology*, 45(3), 1049-1059.
- Ackermann, H.-W., Tremblay, D., Moineau, S. (2004). Long-term bacteriophage preservation. *WFCC Newsletter*, 38, 35-40.
- Ackermann, H. W. (2012). Bacteriophage electron microscopy. *Advances in Virus Research*, 82, 1-32.
- Adams, M. H. (1959). Bacteriophages. New York: Interscience Publishers.
- Adib-Conquy, M., & Cavaillon, J. M. (2007). Stress molecules in sepsis and systemic inflammatory response syndrome. *FEBS letters*, 581(19), 3723-3733.
- Aini I. *Biosecurity in family flocks*. Paper presented at the meeting of World's Poultry Congress, Montréal. August 2000.
- Åkesson, T., Woodward, C., Jönsson, B. (1989). Electric double layer forces in the presence of polyelectrolytes. *The Journal of chemical physics*, 91(4), 2461-2469.
- André, S., Jira, W., Schwind, K.-H., Wagner, H., Schwägele, F. (2010). Chemical safety of meat and meat products. *Meat Science*, 86(1), 38-48.
- Antão, E.-M., Glodde, S., Li, G., Sharifi, R., Homeier, T., Laternus, C., ... Ewers, C. (2008). The chicken as a natural model for extraintestinal infections caused by avian pathogenic *Escherichia coli* (APEC). *Microbial Pathogenesis*, 45(5-6), 361-369.
- Ask, B., Decuypere, E., & van der Waaij, E. H. (2006). Role of thyroid hormones, maternal antibodies, and antibody response in the susceptibility to colibacillosis of broiler genotypes. *Poultry Science*, 85(12), 2141-2148.
- Atterbury, R. J. (2009). Bacteriophage biocontrol in animals and meat products. *Microbial Biotechnology*, 2(6), 601-612.
- Atterbury, R. J., Van Bergen, M. P., Ortiz, F., Lovell, M., Harris, J., De Boer, Barrow, P. A. (2007). Bacteriophage therapy to reduce *Salmonella* colonization of broiler chickens. *Applied and Environmental Microbiology*, 73(14), 4543-4549. *Mikrobiologii, Epidemiologii, I Immunobiologii*, 45(2), 143-145.
- Bagust, J.T. (2013). Poultry health and disease control in developing countries. *Poultry Development Review*, 96-100.

- Bahreini, E., Aghaiypour, K., Abbasalipourkabir, R., Mokarram, A. R., Goodarzi, M. T., Saidijam, M. (2014). Preparation and nanoencapsulation of l-asparaginase II in chitosan-tripolyphosphate nanoparticles and in vitro release study. *Nanoscale Research Letters*, 9(1), 340.
- Barnes, J., Nolan, L. K., Vaillancourt, J.P. (2008). Colibacillosis. In Y. M. Saif (Ed.), *Diseases of Poultry* (pp. 691-695). Oxford: Blackwell Publishers.
- Barratt, G. (1999). Characterization of colloidal drug carrier systems with zeta potential measurements. *Pharmaceutical Technology Europe*, 11, 25–32.
- Berkhoff, H. A., Vinal, A. C. V. (1986). Congo Red Medium to Distinguish between Invasive and Non-Invasive *Escherichia coli* Pathogenic for Poultry. *Avian Diseases*, 30(1), 117–121.
- Bielke, L.R.; Higgins, S.E.; Donoghue, A.M.; Kral, T.; Donoghue, D.J.; Hargis, B.M. Tellez, G.I. (2007a) Evaluation of alternative host bacteria as vehicles for oral administration of bacteriophages. *International Journal Poultry Science*, 6, 758-761.
- Bonacorsi, S., & Bingen, E. (2005). Molecular epidemiology of *Escherichia coli* causing neonatal meningitis. *International Journal of Medical Microbiology: IJMM*, 295(6-7), 373–81.
- Bora, A., Hazarika, N. K., Shukla, S. K., Prasad, K. N., Sarma, J. B., & Ahmed, G. (2014). Prevalence of blaTEM, blaSHV and blaCTX-M genes in clinical isolates of *Escherichia coli* and *Klebsiella pneumoniae* from Northeast India. *Indian Journal of Pathology and Microbiology*, 57(2), 249.
- Boratynski, J., Syper, D., Weber-Dabrowska, B., Lusiak-Szelachowska, M., Pozniak, G., Gorski, A. (2004). Preparation of endotoxin-free bacteriophages. *Cell Molecular Biology Letters*, 9(2), 253–259.
- Borie, C., Albala, I., Sánchez, P., Sánchez, M. L., Ramírez, S., Navarro, C., Robeson, J. (2008). Bacteriophage treatment reduces *Salmonella* colonization of infected chickens. *Avian Diseases*, 52(1), 64–67.
- Bowersock, T. L., Martin, S. (1999). Vaccine delivery to animals. *Advanced Drug Delivery Reviews*, 38(2), 167–194.
- Bozkir, A., & Saka, O. M. (2004). Chitosan nanoparticles for plasmid DNA delivery: effect of chitosan molecular structure on formulation and release characteristics. *Drug Delivery*, 11(2), 107-112.
- Breitbart, M., Wegley, L., Leeds, S., Schoenfeld, T., Rohwer, F. (2004). Phage community dynamics in hot springs. *Applied and Environmental Microbiology*, 70(3), 1633-1640.

- Brüssow, H., Canchaya, C., Hardt, W.-D. (2004). Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion. *Microbiology and Molecular Biology Reviews* : *MMBR*, 68(3), 560–602.
- Bruttin, A., & Brüssow, H. (2005). Human volunteers receiving *Escherichia coli* phage T4 orally: a safety test of phage therapy. *Antimicrobial Agents and Chemotherapy*, 49(7), 2874–2878.
- Brunoghe, R., & Maisin, J. (1921). Essais de therapeutique au moyen du bacteriophage du staphylocoque. *Comptes Rendus Biologies*, 85, 1029-1121.
- Buzea, C., Pacheco, I. I., Robbie, K. (2008). Nanomaterials and nanoparticles: Sources and toxicity. *Biointerphases*, 2(4), 17-172.
- Carey-Smith, G. V., Billington, C., Cornelius, A. J., Hudson, J. A., Heinemann, J. A. (2006). Isolation and characterization of bacteriophages infecting *Salmonella* spp. *FEMS Microbiology Letters*, 258(2), 182–186.
- Caroff, M., & Karibian, D. (2003). Structure of bacterial lipopolysaccharides. *Carbohydrate Research*, 338(23), 2431–2447.
- Carvalho, C. M., Gannon, B. W., Halfhide, D. E., Santos, S. B., Hayes, C. M., Roe, J. M., Azeredo, J. (2010). The in vivo efficacy of two administration routes of a phage cocktail to reduce numbers of *Campylobacter coli* and *Campylobacter jejuni* in chickens. *BMC Microbiology*, 10, 232.
- Chandy, T., & Sharma, C. P. (1990). Chitosan-as a biomaterial. *Biomaterials, Artificial Cells and Artificial Organs*, 18(1), 1–24.
- Chernomordik, A. B. (1990). The chemotherapy of sepsis. *Fel'dsher i akusherka*, 55(3), 24–26.
- Chibani-Chennoufi, S., Sidoti, J., Bruttin, A., Kutter, E., Sarker, S., Brüssow, H. (2004). In vitro and in vivo bacteriolytic activities of *Escherichia coli* phages: implications for phage therapy. *Antimicrobial Agents and Chemotherapy*, 48(7), 2558–2569.
- Clark, J. R., & March, J. B. (2006). Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials. *Trends in Biotechnology*, 24(5), 212–218.
- Coudron, P. E., Moland, E. S., Thomson, K. S. (2000). Occurrence and detection of AmpC beta-lactamases among *Escherichia coli*, *Klebsiella pneumoniae*, and *Proteus mirabilis* isolates at a veterans medical center. *Journal of Clinical Microbiology*, 38(5), 1791-1796.
- Crini, G., & Badot, P. M. (2008). Application of chitosan, a natural aminopolysaccharide, for dye removal from aqueous solutions by adsorption processes using batch studies: a review of recent literature. *Progress in polymer science*, 33(4), 399-447.

- Cruickshank, R. (1975). *Medical microbiology: The practice of medical microbiology*. Edinburgh. Churchill Livingstone.
- Culbertson, R., Osburn, B. I. (1980). The biologic effects of bacterial endotoxin: A short review. *Veterinary Science Communications*, 4(1) 3-14.
- Dehghan, S., Kheiri, M. T., Tabatabaiean, M., Darzi, S., Tafaghodi, M. (2013). Dry-powder form of chitosan nanospheres containing influenza virus and adjuvants for nasal immunization. *Archives of Pharmaceutical Research*, 36(8), 981–992.
- Debarbieux, L., Leduc, D., Maura, D., Morello, E., Criscuolo, A., Grossi, O., Touqui, L. (2010). Bacteriophages can treat and prevent *Pseudomonas aeruginosa* lung infections. *Journal of Infectious Diseases*, 201(7), 1096-1104.
- Dho-moulin, M., Morris, J., Avian, F. (1999). Avian pathogenic *Escherichia coli*. *Veterinary Research*, 30(2-3), 299–316.
- Dini, C., Islan, G. A., de Urreza, P. J., Castro, G. R. (2012). Novel biopolymer matrices for microencapsulation of phages: enhanced protection against acidity and protease activity. *Macromolecular Bioscience*, 12(9), 1200–1208.
- Duriez, P., Clermont, O., Bonacorsi, S., Bingen, E., Chaventré A., Elion, J., Denamur, E. (2001). Commensal *Escherichia coli* isolates are phylogenetically distributed among geographically distinct human populations. *Microbiology*, 147(6), 1671–1676.
- Dong, Q. Y., Chen, M. Y., Xin, Y., Qin, X. Y., Cheng, Z., Shi, L. E., Tang, Z. X. (2013). Alginate - based and protein - based materials for probiotics encapsulation: a review. *International Journal of Food Science and Technology*, 48(7), 1339-1351.
- Ewers, C., Li, G., Wilking, H., Kiessling, S., Alt, K., Ant o, E.-M., Wieler, L. H. (2007). Avian pathogenic, uropathogenic, and newborn meningitis-causing *Escherichia coli*: how closely related are they? *International Journal of Medical Microbiology : IJMM*, 297(3), 163–176
- Federal Department of Agriculture (FDA), Microbiological Safety of Controlled and Modified Atmosphere Packaging of Fresh and Fresh-Cut. USDA. New Hampshire, 2001.
- Feng, Y. Y., Ong, S. L., Hu, J. Y., Tan, X. L., Ng, W. J. (2003). Effects of pH and temperature on the survival of coliphages MS2 and Q β . *Journal of Industrial Microbiology and Biotechnology*, 30(9), 549-552.
- Ferrari, M. (2005). Cancer nanotechnology: opportunities and challenges. *Nature Reviews Cancer*, 5(3), 161–171.

- Fil e, J., T art, F., Suttle, C. A., Krisch, H. M. (2005). Marine T4-type bacteriophages, a ubiquitous component of the dark matter of the biosphere. *Proceedings of the National Academy of Sciences of the United States of America*, 102(35), 12471–12476.
- Fiorentin, L., Vieira, N., Barioni J nior, W. (2005). Use of lytic bacteriophages to reduce *Salmonella Enteritidis* in experimentally contaminated chicken cuts. *Revista Brasileira de Ci ncia Av cola*, 7(4), 255–260.
- Fischetti, V. A. (2006). Using phage lytic enzymes to control pathogenic bacteria. *BMC.Oral Health*, 6 (1),1-4.
- Fischetti, V. A. (2010). Bacteriophage endolysins: A novel anti-infective to control Gram-positive pathogens. *International Journal of Medical Microbiology*, 300(6), 357–362.
- Foley, S. L., Horne, S. M., Giddings, C. W., Robinson, M., Nolan, L. K. (2000). Iss from a Virulent Avian *Escherichia coli*. *Avian Diseases*, 44(1), 185–191.
- Food and agriculture Organization. *The State of Food Insecurity in the World Addressing food insecurity in protracted crises*. Food and Agriculture Organization of the United Nations.Rome. 2010
- FAO Statistical Yearbook, *World Food and Agriculture*. Food and Agriculture Organization of the United Nations. Rome. 2013.
- G ser d, O., Smidsr d, O., Skj k-Br k, G. (1998). Microcapsules of alginate-chitosan– I: A quantitative study of the interaction between alginate and chitosan. *Biomaterials*, 19(20), 1815–1825.
- Gomis, S. M., Watts, T., Riddell, C., Potter, A. A., Allan, B. J. (1997). Experimental Reproduction of *Escherichia coli* Cellulitis and Septicemia in Broiler Chickens. *Avian Diseases*, 41(1), 234–240.
- Gunasekaran, S., Ko, S., Xiao, L. (2007). Use of whey proteins for encapsulation and controlled delivery applications. *Journal of Food Engineering*, 83(1), 31-40.
- Gyles, C. L. (2008). Antimicrobial resistance in selected bacteria from poultry. *Animal Health Research Reviews*, 9(2), 149–158.
- Hafez, H. M. (1999). Poultry meat and food safety: pre-and post-harvest approaches to reduce foodborne pathogens. *World’s Poultry Science Journal*, 55, 269–280.
- Hafez, H. M. (2005). Governmental regulations and concept behind eradication and control of some important poultry diseases. *World’s Poultry Science Journal*, 61(04), 569–582.
- Hafez H. M. Current and Future Challenges of the Poultry Industry. Paper presented at International Seminar AMEVEA, Peru. October 2013.

- Hamelin, K., Bruant, G., El-Shaarawi, A., Hill, S., Edge, T. A., Fairbrother, J., Brousseau, R. (2007). Occurrence of virulence and antimicrobial resistance genes in *Escherichia coli* isolates from different aquatic ecosystems within the St. Clair River and Detroit River areas. *Applied and Environmental Microbiology*, 73(2), 477–484.
- Harry, E. G., Hemsley, L. A. (1965). The relationship between environmental contamination with septicaemia strains of *Escherichia coli* and their incidence in chickens. *The Veterinary Record*, 77, 241–245.
- Hirano, S., Seino, H., Akiyama, Y., Nonaka, I. (1990). Chitosan: a biocompatible material for oral and intravenous administrations. In C. G. Gebelein and R. L. Dunn (Ed.), *Progress in biomedical polymers* (pp. 283-290). Berlin: Springer.
- Holah, J. T., Taylor, J. H., Dawson, D. J., Hall, K. E. (2002). Biocide use in the food industry and the disinfectant resistance of persistent strains of *Listeria monocytogenes* and *Escherichia coli*. *Journal of Applied Microbiology*, 92(1), 111–120.
- Huff, G. R., Huff, W. E., Rath, N. C., Tellez, G. (2006). Limited treatment with β -1, 3/1, 6-glucan improves production values of broiler chickens challenged with *Escherichia coli*. *Poultry Science*, 85(4), 613–618.
- Huff, W. E., Huff, G. R., Rath, N. C., Balog, J. M., Donoghue, A. M. (2004). Therapeutic efficacy of bacteriophage and Baytril (enrofloxacin) individually and in combination to treat colibacillosis in broilers. *Poultry Science*, 83(12), 1944–1947.
- Huff, W. E., Huff, G. R., Rath, N. C., Balog, J. M., & Donoghue, A. M. (2005). Alternatives to antibiotics: utilization of bacteriophage to treat colibacillosis and prevent foodborne pathogens. *Poultry Science*, 84(4), 655–659.
- Huff, W. E., Huff, G. R., Rath, N. C., Balog, J. M., Xie, H., Moore, P. A., Donoghue, A. M. (2002). Prevention of *Escherichia coli* Respiratory Infection in Broiler Chickens with Bacteriophage (SPR02). *Poultry Science*, 81(4), 437–441.
- Huff, W. E., Huff, G. R., Rath, N. C., & Donoghue, A. M. (2013). Method of administration affects the ability of bacteriophage to prevent colibacillosis in 1-day-old broiler chickens. *Poultry Science*, 92(4), 930–934.
- Huff, W., Huff, G., Rath, N., Balog, J., Donoghue, A. (2003). Evaluation of aerosol spray and intramuscular injection of bacteriophage to treat an *Escherichia coli* respiratory infection. *Poultry Science*, 82(7), 1108–1112.
- Hunter, R. J. (1981). *Zeta Potential in Colloid Science: Principles and Applications*. New York: Academic Press
- Huyghebaert, G., Ducatelle, R., Van Immerseel, F. (2011). An update on alternatives to antimicrobial growth promoters for broilers. *Veterinary Journal*, 187(2), 182–188.

- International Food Policy Research Institute (2000). *Research Perspectives: Agriculture and food production*. Waikato, New Zealand.
- Jakobsen, L., Hammerum, A. M., Frimodt-Møller, N. (2010). Detection of clonal group A *Escherichia coli* isolates from broiler chickens, broiler chicken meat, community-dwelling humans, and urinary tract infection (UTI) patients and their virulence in a mouse UTI model. *Applied and Environmental Microbiology*, 76(24), 8281–8284.
- Jamaluddin A.A. *Broiler Industry in Malaysia*. Paper presented at the meeting of the World Poultry Science Association and World Veterinary Poultry Association Malaysia Branches, Kuala Lumpur. November 2013.
- Jameela, S. R., Jayakrishnan, A. (1995). Glutaraldehyde cross-linked chitosan microspheres as a long acting biodegradable drug delivery vehicle: studies on the in vitro release of mitoxantrone and in vivo degradation of microspheres in rat muscle. *Biomaterials*, 16(10), 769–775.
- Janež, N., & Loc-Carrillo, C. (2013). Use of phages to control *Campylobacter* spp. *Journal of Microbiological Methods*, 95(1), 68–75.
- Jepson, C. D., March, J. B. (2004). Bacteriophage lambda is a highly stable DNA vaccine delivery vehicle. *Vaccine*, 22(19), 2413-2419.
- Joerger, R. (2003). Alternatives to antibiotics: bacteriocins, antimicrobial peptides and bacteriophages. *Poultry Science*, 82(4), 640–647.
- Johnson, J. R., Kuskowski, M. A., Smith, K., O’Bryan, T. T., Tatini, S. (2005). Antimicrobial-resistant and extraintestinal pathogenic *Escherichia coli* in retail foods. *The Journal of Infectious Diseases*, 191(7), 1040–1049.
- Johnson, J. R., & Russo, T. A. (2002). Uropathogenic *Escherichia coli* as agents of diverse non-urinary tract extraintestinal infections. *The Journal of Infectious Diseases*, 186(6), 859–864.
- Johnson, R. P., Gyles, C. L., Huff, W. E., Ojha, S., Huff, G. R., Rath, N. C., & Donoghue, A. M. (2008). Bacteriophages for prophylaxis and therapy in cattle, poultry and pigs. *Animal Health Research Reviews*, 9(2), 201–215.
- Johnson, T. J., Kariyawasam, S., Wannemuehler, Y., Mangiamiele, P., Johnson, S. J., Doetkott, C., Nolan, L. K. (2007). The Genome Sequence of Avian Pathogenic *Escherichia coli* strain O1:K1:H7 Shares Strong Similarities with Human Extraintestinal Pathogenic *E. coli* Genomes. *Journal of Bacteriology*, 189(12), 4554–4554.
- Johnson, T. J., Skyberg, J., Nolan, L. K. (2009). Multiple antimicrobial resistance region of a putative virulence plasmid from an *Escherichia coli* isolate incriminated in avian colibacillosis. *Avian Diseases*, 48(2), 351–360.

- Kariyawasam, S., Wilkie, B. N., & Gyles, C. L. (2009). Construction, characterization, and evaluation of the vaccine potential of three genetically defined mutants of avian pathogenic *Escherichia coli*. *Avian Diseases*, 48(2), 287–299.
- Kawato, Y., Yasuike, M., Nakamura, Y., Shigenobu, Y., Fujiwara, A., Sano, M., Nakai, T. (2015). Complete genome sequence analysis of two *Pseudomonas plecoglossicida* phages, potential therapeutic agents. *Applied and Environmental Microbiology*, 81(3), 874–881.
- Keane, W. F., & Maddy, M. F. (1989). Host defenses and infectious complications in maintenance hemodialysis patients. In J. F. Maher (Ed.), *Replacement of renal function by dialysis* (pp. 865-880). Netherlands: Springer Publisher.
- Keary, R., McAuliffe, O., Ross, R. P., Hill, C., Mahony, J. O., Coffey, A. (2013). Bacteriophages and their endolysins for control of pathogenic bacteria. In A. Méndez-Vilas (Ed.), *Microbial pathogens and strategies for combating them: science, technology and education* (pp. 1028–1040) Spain: Formatex.
- Khor, E., & Lim, L. Y. (2003). Implantable applications of chitin and chitosan. *Biomaterials*, 24(13), 2339-2349.
- Kim, S., Jo, A., Ahn, J. (2015). Application of chitosan-alginate microspheres for the sustained release of bacteriophage in simulated gastrointestinal conditions. *International Journal of Food Science and Technology*, 50(4), 913–918.
- Knaul, J. Z., Hudson, S. M., Creber, K. A. (1999). Improved mechanical properties of chitosan fibers. *Journal of Applied Polymer Science*, 72(13), 1721-1732.
- Koo, J., DePaola, A., Marshall, D. L. (2000). Effect of simulated gastric fluid and bile on survival of *Vibrio vulnificus* and *Vibrio vulnificus* phage. *Journal of Food Protection*, 63(12), 1665–1669.
- Korehei, R., & Kadla, J. F. (2014). Encapsulation of T4 bacteriophage in electrospun poly (ethylene oxide)/cellulose diacetate fibers. *Carbohydrate polymers*, 100, 150-157.
- Lau, G. L., Sieo, C. C., Tan, W. S., Hair-Bejo, M., Jalila, A., Ho, Y. W. (2010). Efficacy of a bacteriophage isolated from chickens as a therapeutic agent for colibacillosis in broiler chickens. *Poultry Science*, 89(12), 2589–2596.
- Lazarus, B., Paterson, D. L., Mollinger, J. L., Rogers, B. A. (2015). Do human extraintestinal *Escherichia coli* infections resistant to expanded-spectrum cephalosporins originate from food-producing animals? A systematic review. *Clinical Infectious Diseases*, 60(3), 439–452.
- Leiman, P. G., Chipman, P. R., Kostyuchenko, V. A., Mesyanzhinov, V. V., & Rossmann, M. G. (2004). Three-dimensional rearrangement of proteins in the tail of bacteriophage T4 on infection of its host. *Cell*, 118(4), 419–429.

- Levy, S. B. (2001). Antibiotic resistance: consequences of inaction. *Clinical Infectious Diseases*, 33(3), 124–129.
- Lewis, K. (2005). Persister cells and the riddle of biofilm survival. *Biochemistry (Moscow)*, 70(2), 267–274.
- Li, G., Laturnus, C., Ewers, C., Wieler, L. H. (2005). Identification of genes required for avian *Escherichia coli* septicemia by signature-tagged mutagenesis. *Infection and Immunity*, 73(5), 2818–2827.
- Lima-Filho, J. V., Martins, L. V., Nascimento, D. C. de O., Ventura, R. F., Batista, J. E. C., Silva, A. F. B., Evêncio-Neto, J. (2013). Zoonotic potential of multidrug-resistant extraintestinal pathogenic *Escherichia coli* obtained from healthy poultry carcasses in Salvador, Brazil. *The Brazilian Journal of Infectious Diseases*, 17(1), 54–61.
- Lindberg, B., Lonngren, J., Ruden, U., Simmons, D. A. R. (1973). A Reinvestigation of Shigella flexneri O-Antigens by Methylation Analysis. *European Journal of Biochemistry*, 32(1), 15–18.
- Liu, H., Du, Y., Wang, X., Sun, L. (2004). Chitosan kills bacteria through cell membrane damage. *International journal of food microbiology*, 95(2), 147-155.
- Liu, N., Chen, X.-G., Park, H.-J., Liu, C.-G., Liu, C.-S., Meng, X.-H., Yu, L.J. (2006). Effect of MW and concentration of chitosan on antibacterial activity of *Escherichia coli*. *Carbohydrate Polymers*, 64(1), 60–65.
- Liu, Z., Lv, D., Liu, S., Gong, J., Wang, D., Xiong, M., Tan, X. (2013). Alginate-coated chitosan nanoparticles loaded with legumain DNA vaccine: effect against breast cancer in mice. *PLoS One*, 8(4),1-11.
- Ma, Y., Pacan, J. C., Wang, Q., Xu, Y., Huang, X., Korenevsky, A., Sabour, P. M. (2008). Microencapsulation of bacteriophage Felix O1 into chitosan-alginate microspheres for oral delivery. *Applied and environmental microbiology*, 74(15), 4799-4805.
- Müller, M., Wurtz, M., Kellenberger, E., Aebi, U. (1991). Physiological, morphological, and physicochemical characterization of a novel *Escherichia coli* bacteriophage, phage MM. *Journal of structural biology*, 106(1), 17-30.
- Majid, R. Bin, & Hassan, S. (2014). Performance of broiler contract farmers: A case study in Perak, Malaysia. *UMK Procedia*, 1, 18–25.
- Man, Y. C., & Swe, P. Z. (1995). Thermal analysis of failed-batch palm oil by differential scanning calorimetry. *Journal of the American Oil Chemists' Society*, 72(12), 1529-1532.
- Manges, A. R., Johnson, J. R. (2012). Food-borne origins of *Escherichia coli* causing extraintestinal infections. *Clinical Infectious Diseases*, 55(5), 712–719.

- Manning, S. D., Motiwala, A. S., Springman, A. C., Qi, W., Lacher, D. W., Ouellette, L. M., Whittam, T. S. (2008). Variation in virulence among clades of *Escherichia coli* O157:H7 associated with disease outbreaks. *Proceedings of the National Academy of Sciences of the United States of America*, 105(12), 4868-4873.
- Mao, H.-Q., Roy, K., Troung-Le, V. L., Janes, K. A., Lin, K. Y., Wang, Y., Leong, K. W. (2001). Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. *Journal of Controlled Release*, 70(3), 399-421.
- Mathew, B., Rangapriya, M., Rajendran, N. N. (2014). Evaluation and stability study of Rifampicin loaded chitosan Nanoparticles, *World Journal of Pharmacy and Pharmaceutical Sciences* 3(11), 609-624.
- Maukonen, J., M??tt??, J., Wirtanen, G., Raaska, L., Mattila-Sandholm, T., & Saarela, M. (2003). Methodologies for the characterization of microbes in industrial environments: A review. *Journal of Industrial Microbiology and Biotechnology*, 30(6), 327-356.
- Mellata, M., Dho-Moulin, M., Dozois, C. M., Curtiss, R., Brown, P. K., Arn ? P., Bre, A. (2003). Role of virulence factors in resistance of Avian Pathogenic *Escherichia coli* to serum and in pathogenicity role of virulence factors in resistance of Avian Pathogenic *Escherichia coli* to serum and in pathogenicity. *Infection and Immunity*, 71(1), 536-540.
- Merril, C. R., Scholl, D., Adhya, S. (2006). Phage therapy. *Bacteriophages*, 2, 725-741.
- Miller, E. S., Kutter, E., Mosig, G., Arisaka, F., Kunisawa, T., Ruger, W. (2003). Bacteriophage T4 Genome. *Microbiology and Molecular Biology Reviews*, 67(1), 86-156.
- Mora, A., L?pez, C., Dabhi, G., Blanco, M., Blanco, J. E., Alonso, M. P., ... Blanco, J. (2009). Extraintestinal pathogenic *Escherichia coli* O1:K1:H7/NM from human and avian origin: detection of clonal groups B2 ST95 and D ST59 with different host distribution. *BMC Microbiology*, 9(132), 1-11.
- Moulin-Schouleur, M., R?p?rant, M., Laurent, S., Br?e, A., Mignon-Grasteau, S., Germon, P., Schouler, C. (2007). Extraintestinal pathogenic *Escherichia coli* strains of avian and human origin: link between phylogenetic relationships and common virulence patterns. *Journal of Clinical Microbiology*, 45(10), 3366-3376.
- Nakamura, K., Maeda, M., Imada, Y., Imada, T., Sato, K. (1985). Pathology of spontaneous colibacillosis in a broiler flock. *Veterinary Pathology*, 22(6), 592-597.
- Newell, D. G., Koopmans, M., Verhoef, L., Duizer, E., Aidara-Kane, A., Sprong, H., Kruse, H. (2010). Food-borne diseases - the challenges of 20 years ago still persist while new ones continue to emerge. *International Journal of Food Microbiology*, 139, 3-15.

- Nidhin, M., Indumathy, R., Sreeram, K. J., Nair, B. U. (2008). Synthesis of iron oxide nanoparticles of narrow size distribution on polysaccharide templates. *Bulletin of Materials Science*, 31(1), 93–96.
- Niu, Y. D., McAllister, T. A., Xu, Y., Johnson, R. P., Stephens, T. P., Stanford, K. (2009). Prevalence and impact of bacteriophages on the presence of *Escherichia coli* O157:H7 in feedlot cattle and their environment. *Applied and Environmental Microbiology*, 75(5), 1271–1278.
- Oliveira, A., Sillankorva, S., Quinta, R., Henriques, A., Sereno, R., Azeredo, J. (2009). Isolation and characterization of bacteriophages for avian pathogenic *E. coli* strains. *Journal of Applied Microbiology*, 106(6), 1919–1927.
- Oliveira, A., Sereno, R., Azeredo, J. (2010). In vivo efficiency evaluation of a phage cocktail in controlling severe colibacillosis in confined conditions and experimental poultry houses. *Veterinary Microbiology*, 146(3-4), 303–308.
- Oliveira, A., Sillankorva, S., Quinta, R., Henriques, A., Sereno, R., Azeredo, J. (2009). Isolation and characterization of bacteriophages for avian pathogenic *E. coli* strains. *Journal of Applied Microbiology*, 106(6), 1919–1927.
- Olson, M. R., Axler, R. P., Hicks, R. E. (2004). Effects of freezing and storage temperature on MS2 viability. *Journal of Virological Methods*, 122(2), 147–152.
- Ormańń A.-M., & Jalasvuori, M. (2013). Phage therapy: Should bacterial resistance to phages be a concern, even in the long run? *Bacteriophage*, 3(1),1-3.
- Paul, J. H., Sullivan, M. B., Segall, A. M., Rohwer, F. (2002). Marine phage genomics. *Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology*, 133(4), 463–476.
- Piercy, D. W. T., & West, B. (1976). Experimental *Escherichia coli* infection in broiler chickens: course of the disease induced by inoculation via the air sac route. *Journal of Comparative Pathology*, 86(2), 203-210.
- Pignatello, R., Ricupero, N., Bucolo, C., Maugeri, F., Maltese, A., Puglisi, G. (2006). Preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromene. *AAPS PharmSciTech*, 7(1), 192-198.
- Pollard, E., Woodyatt, S. (1964). The Effect of Temperature on the Formation of T1 and T2r Bacteriophage. *Biophysical Journal*, 4(5), 367–385.
- Puttipipatkachorn, S., Nunthanid, J., Yamamoto, K., Peck, G. E. (2001). Drug physical state and drug-polymer interaction on drug release from chitosan matrix films. *Journal of controlled release*, 75(1), 143-153.
- Rampino, A., Borgogna, M., Blasi, P., Bellich, B., Cesàro, A. (2013). Chitosan nanoparticles: Preparation, size evolution and stability. *International Journal of Pharmaceutics*, 455(1), 219–228.

- Richardson, S. W., Kolbe, H. J., Duncan, R. (1999). Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA. *International Journal of Pharmaceutics*, 178(2), 231-243.
- Ron, E. Z. (2006). Host specificity of septicemic *Escherichia coli*: human and avian pathogens. *Current Opinion in Microbiology*, 9(1), 28–32.
- Russo, T. A., Johnson, J. R. (2003). Medical and economic impact of extraintestinal infections due to *Escherichia coli*: Focus on an increasingly important endemic problem. *Microbes and Infection*, 5(5), 449–456.
- Saberfar, E., Pourakbari, B., Chabokdavan, K., Dolatshahi, F. T. (2008). Antimicrobial Susceptibility of *Escherichia coli* Isolated from Iranian Broiler Chicken Flocks, 2005-2006. *The Journal of Applied Poultry Research*, 17(2), 302–304.
- Sahin, O., Zhang, Q., Meitzler, J. C., Harr, B. S., Morishita, T. Y., Mohan, R. (2001). Prevalence, Antigenic Specificity, and Bactericidal Activity of Poultry Anti-*Campylobacter* Maternal Antibodies. *Applied and Environmental Microbiology*, 67(9), 3951–3957.
- Sa ěd, N., Aider, M. (2014). Zeta Potential and turbidimetry analyzes for the evaluation of chitosan/phytic Acid complex formation. *Journal of Food Research*, 3(2), 71-81.
- Salehi, T. Z., Tabatabaei, S., Karimi, V., Fasaei, B. N., Derakhshandeh, A., Jahromi, O. A. N. (2012). Assessment of immunity against avian colibacillosis induced by an *aroA* mutant containing increased serum survival gene in broilers. *Brazilian Journal of Microbiology*, 43(1), 363–370.
- Schoubben, A., Blasi, P., Marenzoni, M. L., Barberini, L., Giovagnoli, S., Cirotto, C., Ricci, M. (2013). Capreomycin supergenerics for pulmonary tuberculosis treatment: preparation, in vitro, and in vivo characterization. *European Journal of Pharmaceutics and Biopharmaceutics*, 83(3), 388–395.
- Sharma, J., Sharma, M., Ray, P. (2010). Detection of TEM and SHV genes in *Escherichia coli* and *Klebsiella pneumoniae* isolates in a tertiary care hospital from India. *Indian Journal of Medical Research*, 132(3), 332-336.
- Sheldon, I. M., Rycroft, A. N., Dogan, B., Craven, M., Bromfield, J. J., Chandler, A., Simpson, K. W. (2010). Specific strains of *Escherichia coli* are pathogenic for the endometrium of cattle and cause pelvic inflammatory disease in cattle and mice. *PloS One*, 5(2), 91-92.
- Silva, J. A., Macedo, G. P., Rodrigues, D. S., Giordano, R. L. C., Gon çalves, L. R. B. (2012). Immobilization of *Candida antarctica* lipase B by covalent attachment on chitosan-based hydrogels using different support activation strategies. *Biochemical Engineering Journal*, 60, 16-24.

- Skyberg, J. A., Johnson, T. J., Johnson, J. R., Clabots, C., Logue, C. M., Nolan, L. K. (2006). Acquisition of avian pathogenic *Escherichia coli* plasmids by a commensal *E. coli* isolate enhances its abilities to kill chicken embryos, grow in human urine, and colonize the murine kidney. *Infection and Immunity*, 74(11), 6287–6292.
- Solov'eva, T., Davydova, V., Krasikova, I., Yermak, I. (2013). Marine compounds with therapeutic potential in gram-negative sepsis. *Marine Drugs*, 11(6), 2216–2229.
- Song, Y., Dou, H., Gong, W., Liu, X., Yu, Z., Li, E., Hou, Y. (2013). Bis-N-norgliovictin, a small-molecule compound from marine fungus, inhibits LPS-induced inflammation in macrophages and improves survival in sepsis. *European Journal of Pharmacology*, 705(1-3), 49–60.
- Stecher, B., & Hardt, W.-D. (2008). The role of microbiota in infectious disease. *Trends in Microbiology*, 16(3), 107–114.
- Stordeur, P., Marlier, D., Blanco, J., Oswald, E., Biet, F., Dho-Moulin, M., Mainil, J. (2002). Examination of *Escherichia coli* from poultry for selected adhesin genes important in disease caused by mammalian pathogenic *E. coli*. *Veterinary Microbiology*, 84(3), 231–241.
- Subramaniam, G., Palasubramaniam, S., Navaratnam, P. (2006). SHV-5 extended-spectrum beta-lactamases in clinical isolates of *Escherichia coli* in Malaysia. *Indian Journal of Medical Microbiology*, 24(3), 205–207.
- Sulakvelidze, A. (2011). The challenges of bacteriophage therapy. *Industrial Pharmacy*, 45(31), 14–18.
- Swenson, M.J. (1970). Physiologic properties, cellular chemical constituents of blood. In Duke. H.H (Ed.), *Duke's Physiology of Domestic Animals* (pp. 20-61). Ithaca: Cornell University Press.
- Taj, M. K., Ling, J. X., Bing, L. L., Qi, Z., Taj, I., Hassani, T. M., Yunlin, W. (2014). Effect of dilution, temperature and pH on the lysis activity of t4 phage against *E. coli* BL21. *Journal of Animal and Plant Sciences*, 24(4), 1252-1255.
- Thong, K. L., Lim, K. T., Yasin, R., Yeo, C. C., Puthuchery, S. (2009). Characterization of multidrug resistant ESBL-Producing *Escherichia coli* isolates from hospitals in Malaysia. *Journal of Biomedicine and Biotechnology*, 2(5), 3-10.
- Tissera, S., Mae Lee, S. (2013). Isolation of extended spectrum lactamase (ESBL) producing bacteria from urban surface waters in Malaysia. *Malaysian Journal of Medical Sciences*, 20(3), 14-22.
- Turner, K. M., Restaino, L., Frampton, E. W. (2000). Efficacy of chromocult coliform agar for coliform and *Escherichia coli* detection in foods. *Journal of Food Protection*, 63(4), 539–541.

- Ulmer, E., Hacker, J., Fasske, E., & Schmidt, G. (1987). Isolation and characterization of coliphage Ω 18A specific for *Escherichia coli* O18ac strains. *Zentralblatt Für Bakteriologie, Mikrobiologie Und Hygiene. Series A: Medical Microbiology, Infectious Diseases, Virology, Parasitology*, 266(3-4), 403–411.
- Vale, P. F., Stjernman, M., & Little, T. J. (2008). Temperature-dependent costs of parasitism and maintenance of polymorphism under genotype-by-environment interactions. *Journal of Evolutionary Biology*, 21(5), 1418–1427.
- Van den Bogaard, A. E. (2001). Antibiotic resistance of faecal *Escherichia coli* in poultry, poultry farmers and poultry slaughterers. *Journal of Antimicrobial Chemotherapy*, 47(6), 763–771.
- Vandekerchove, D., De Herdt, P., Laevens, H., & Pasmans, F. (2004). Colibacillosis in caged layer hens: characteristics of the disease and the aetiological agent. *Avian Pathology: Journal of the W.V.P.A.*, 33(2), 117–125.
- Vandekerchove, D., Vandemaële, F., Adriaensen, C., Zaleska, M., Hernalsteens, J. P., De Baets, L., Pasmans, F. (2005). Virulence-associated traits in avian *Escherichia coli*: Comparison between isolates from colibacillosis-affected and clinically healthy layer flocks. *Veterinary Microbiology*, 108(1-2), 75–87.
- Wagner, E., Hewlett, M., Bloom, D., Camerini, D. (2009). *Basic Virology*. New Jersey: Blackwell Publishing.
- Wang, G., Pan, L., Zhang, Y., Wang, Y., Zhang, Z., Lü, J., Jiang, S. (2011). Intranasal delivery of cationic PLGA nano/microparticles- loaded FMDV DNA vaccine encoding IL-6 elicited protective immunity against FMDV challenge. *PLoS ONE*, 6(11), 1-14.
- Warren, J. C., Hatch, M. T. (1969). Survival of T3 coliphage in varied extracellular environments. I. Viability of the coliphage during storage and in aerosols. *Applied Microbiology*, 17(2), 256–261.
- Watanabe, R., Matsumoto, T., Sano, G., Ishii, Y., Tateda, K., Sumiyama, Y., Yamaguchi, K. (2007). Efficacy of bacteriophage therapy against gut-derived sepsis caused by *Pseudomonas aeruginosa* in mice. *Antimicrobial agents and chemotherapy*, 51(2), 446-452.
- Weinstock-Guttman, B., Baier, M., Park, Y., Feichter, J., Lee-Kwen, P., Gallagher, E. Rudick, R. (2005). Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. *Prostaglandins, Leukotrienes, and Essential Fatty Acids*, 73(5), 397–404.
- White, A. P., Sibley, K. A., Sibley, C. D., Wasmuth, J. D., Schaefer, R., Surette, M. G., Neumann, N. F. (2011). Intergenic sequence comparison of *Escherichia coli* isolates reveals lifestyle adaptations but not host specificity. *Applied and Environmental Microbiology*, 77(21), 7620–7632.

- Williams, K.L. (2001b). Endotoxin structure, function and activity. In K.L. Williams (Ed.), *Endotoxins, Pyrogens, LAL Testing, and Depyrogenation* (pp. 27-38). New York: Marcel Dekker.
- World Poultry. *Malaysian poultry industry meeting domestic demand*, Reed Business Information: Surrey, 2014.
- Xu, Y., & Du, Y. (2003). Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. *International Journal of Pharmaceutics*, 250(1), 215–226.
- Yousseff, F. M., Ahmed, M. A., Mansour, D. H. (2008). Clinical, Pathological and bacteriological investigations on Air sacculitis in chickens in Ismailia Province (Egypt). *Journal of Agricultural and Veterinary Sciences*, 1(2), 71-79.
- Zanella, A., Alborali, G. L., Bardotti, M., Candotti, P., Guadagnini, P. F., Martino, P. A., & Stonfer, M. (2000). Severe *Escherichia coli* O111 septicaemia and polyserositis in hens at the start of lay. *Avian Pathology : Journal of the W.V.P.A.*, 29(4), 311–317.
- Zivot, J. B., & Hoffman, W. D. (1995). Pathogenic effects of endotoxin. *New Horizons*, 3(2), 267–275.